The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Completed · Phase 1

Conditions studied: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence

In brief

This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.

Key facts

Study ID

NCT00911235

Run by

Pfizer

People needed

28

Starts

2009-05-01

Expected to finish

2009-07-01

Last updated by the study team

2011-06-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects between the ages of 18 and 55 years

You may not qualify if…

• Not healthy subjects. subjects with acute or chronic medical or psychiatric condition or laboratory abnormality

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.